Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 11/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14706531 | 0.90 | CACNA1I (0.48) | CACNA1IKCNH2CACNA1HCACNA1GPOLB | |
| SCHEMBL4280786 | 0.89 | CACNA1I (0.63) | CACNA1IKCNH2CACNA1HCACNA1GPOLB | |
| SCHEMBL4269380 | 0.89 | CACNA1H (0.56) | CACNA1IKCNH2CACNA1HCACNA1GPOLB | |
| SCHEMBL8373060 | 0.87 | CACNA1I (0.52) | CACNA1IKCNH2CACNA1HCACNA1GCYP2D6 | |
| SCHEMBL8376177 | 0.86 | CACNA1H (0.58) | CACNA1IKCNH2CACNA1HCACNA1GCYP2D6 | |
| SCHEMBL4280566 | 0.81 | CACNA1I (0.52) | CACNA1IKCNH2CACNA1HCACNA1GPOLB | |
| SCHEMBL4274816 | 0.81 | CACNA1I (0.56) | CACNA1IKCNH2CACNA1HCACNA1GCYP2D6 | |
| SCHEMBL4282748 | 0.81 | CACNA1I (0.74) | CACNA1IKCNH2CACNA1HCACNA1GCYP2D6 | |
| SCHEMBL4270099 | 0.79 | PIM1 (0.51) | CACNA1IKCNH2CACNA1HCACNA1GKDM4E | |
| SCHEMBL14770272 | 0.78 | CCR2 (0.55) | CACNA1IKCNH2CACNA1HPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CACNA1I 4/4885KCNH2 60/4885CACNA1H 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.